Dynatrace vs Fair Isaac
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Dynatrace and Fair Isaac side by side, using each one’s latest annual report. Here is what stands out:
- Dynatrace is the larger business, with $2.0B of revenue in fiscal 2026 against $2.0B for Fair Isaac.
- Dynatrace grew revenue faster (18.8%, against 15.9%).
- Fair Isaac kept more of each dollar of sales as operating profit (46.5% operating margin, against 12.2%).
- Fair Isaac turned more of its sales into free cash flow (38.7% FCF margin, against 26.2%).
- Fair Isaac earned a higher return on the capital invested in it (65.6%, against 9.0%).
- Investors pay more for each dollar of Dynatrace’s earnings: a P/E of 128.4x against 20.5x for Fair Isaac.
Who comes out ahead
Of the 9 measures where higher (or lower) is clearly better, how many each company leads.
Dynatrace
DT
2/9
Revenue growth5-year growth
Fair Isaac
FICO
7/9
Gross marginOperating marginNet marginFCF marginReturn on capitalPiotroski F-scoreShare count change
Side by side
Best in the row
| Latest fiscal year | DT FY26 | FICO FY25 |
|---|---|---|
| Size | ||
| Market cap | $18.8B | $16.1B |
| Revenue | $2.0B | $2.0B |
| Free cash flow | $530M | $770M |
| Net income | $163M | $652M |
| Growth | ||
| Revenue growth | 18.8% | 15.9% |
| 5-year growth | 23.5% | 9.0% |
| Share count change | 0.0% | −2.1% |
| Profitability | ||
| Gross margin | 81.6% | 82.2% |
| Operating margin | 12.2% | 46.5% |
| Net margin | 8.1% | 32.8% |
| FCF margin | 26.2% | 38.7% |
| Return on capital | 9.0% | 65.6% |
| Return on equity | 6.2% | — |
| Balance sheet | ||
| Net debt | −$1.2B | $2.9B |
| Net debt / EBITDA | — | 3.1x |
| Dividends and buybacks | $479M | $1.4B |
| Valuation & quality | ||
| P/E | 128.4x | 20.5x |
| Piotroski F-score | 4 | 7 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.

